Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06365840
PHASE2

A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor

Sponsor: ImmuneOncia Therapeutics Inc.

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to determine the efficacy of IMC-001 in metastatic or locally advanced TMB-H solid tumor patients.

Official title: PHASE 2 STUDY OF IMC-001 IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TMB-H SOLID TUMOR

Key Details

Gender

All

Age Range

19 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2025-01-13

Completion Date

2029-08

Last Updated

2026-04-17

Healthy Volunteers

No

Interventions

DRUG

IMC-001

All participants will receive the study drug, IMC-001, at 20 mg/kg Q2W via IV infusion over 60 minutes.

Locations (4)

National Cancer Center

Goyang, South Korea

Seoul National University Bundang Hospital

Seongnam, South Korea

Samsung Medical Center

Seoul, South Korea

Severance Hospital

Seoul, South Korea